>亚太中枢性性早熟 (CPP) 治疗市场，按类型（药物、手术）、月份（1 个月、3 个月、6 个月、其他）、给药途径（肠外、口服、植入、其他）、性别（女孩、男孩）、最终用户（医院、专科诊所、家庭护理、其他）、分销渠道（医院药房、零售药房、网上药房、其他）划分 - 行业趋势和预测到 2030 年。
亚太中枢性性早熟 (CPP) 治疗市场分析及规模
近年来，中枢性性早熟 (CPP) 治疗市场预计将在 2023-2030 年预测期内快速增长。促性腺激素释放激素 (GnRH) 激动剂可能被广泛用于治疗 CPP，因为它们可以限制内源性 GnRH 的刺激作用并增加骨骼发育，从而避免性早熟。据观察，Triptodor、Lupron Depot-Ped（醋酸亮丙瑞林）和 Supprelin LA（醋酸组氨瑞林）是目前市场上三种获批的中枢性性早熟治疗药物
Data Bridge Market Research 分析了 2023-2030 年预测期内中枢性性早熟 (CPP) 治疗市场的增长率。在上述预测期内，中枢性性早熟 (CPP) 治疗市场的预期复合年增长率趋于 8% 左右。2022 年市场价值为 2.4 亿美元，到 2030 年将增长至 4.442 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。
亚太中枢性性早熟 (CPP) 治疗市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
类型（药物、手术）、月份（1 个月、3 个月、6 个月、其他）、给药途径（肠外、口服、植入、其他）、性别（女孩、男孩）、最终用户（医院、专科诊所、家庭护理、其他）、分销渠道（医院药房、零售药房、网上药房、其他） |
|
覆盖国家 |
亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 其他地区 |
|
涵盖的市场参与者 |
Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Ipsen Pharma (France), Arbor Pharmaceuticals (U.S.), Tolmar Pharmaceuticals, Inc. (U.S.), GP Pharm (Spain), Debiopharm (Switzerland), DAEWOONG PHARMACEUTICAL CO.,LTD (South Korea), Sun Pharmaceutical Industries Ltd. (India), Takeda Pharmaceutical Company Limited (Japan), Endo International plc (Ireland), AstraZeneca (U.K.) |
|
Market Opportunities |
|
Market Definition
Central precocious puberty (CPP) treatment consists of features such as wide presence of novel pipeline drugs that will impact in launching several new products by the manufacturers into the central precocious puberty (CPP) treatment market that will increase its demand as well as high demand of disease specific treatment which leads the demand of accurate central precocious puberty (CPP) treatment. The mutations in the MKRN3 gene are the most commonly known genetic cause of central precocious puberty (CPP).
Asia-Pacific Central Precocious Puberty (CPP) Treatment Market Dynamics
Drivers
- Increasing Product Launches and Collaborations
Several product launches and agreements are also started by the major companies’ globally which are also increasing the central precocious puberty (CPP) treatment market. For instance, AbbVie Inc. collaborated with Scripps Research in december 2019, which is a company that is focused on development of new therapeutic approaches to deal with the usual rare diseases. This collaboration aided the company to treat numerous kinds of diseases by improving its drug development procedure which will lead to earn more economic benefit. Furthermore, collaboration, business expansion, product launches, awards and several recognition, also joint ventures and other strategies by the market players is increasing the market growth in the central precocious puberty (CPP) treatment market which also aids in the benefit for organization to further improve their offering for central precocious puberty treatment.
Opportunities
- Increasing Prevalence of CPP in Girls
It has been witnessed that girls segment is dominating in the central precocious puberty (CPP) treatment market as the prevalence of CPP is less common in boys compared to girls and it has the wide presence of high female ratio than the male population. One in every 5,000 to 10,000 girls is seen to be suffering from central precocious puberty. Though the occurrence of the illness is not so clear in boys, it is less widespread in boys. Thus, this boosts the market growth.
- Rising Adoption of Direct Tender Segment
The direct tender channel is hugely increasing the market growth as the drugs are used for the central precocious puberty (CPP) treatment which can be procured through direct tender on reasonable price and the patients receive treatment for extended period of time. Thus, this factor enhances the market growth.
限制/挑战
- 治疗费用高昂
有几种治疗方法需要手术和高端药物，费用非常高昂。经济状况较差的群体无法获得这些治疗程序。因此，这一因素阻碍了市场的增长，因为治疗方案并不是对所有经济群体都可行的。
- 缺乏报销政策
中枢性性早熟 (CPP) 治疗缺乏报销，预计会限制市场增长。公立和私立付款人均不报销大部分治疗服务。此类服务的成本差异很大，无法标准化。因此，这一因素阻碍了市场增长。
本中枢性性早熟 (CPP) 治疗市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关中枢性性早熟 (CPP) 治疗市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。
亚太中枢性性早熟 (CPP) 治疗市场范围
中枢性性早熟 (CPP) 治疗市场根据类型、月份、给药途径、性别、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
类型
- 药物
- 外科手术
月
- 1 个月
- 3 个月
- 6个月
- 其他的
给药途径
- 肠外
- 口服
- 植入物
- 其他的
性别
- 女孩们
- 男孩们
最终用户
- 医院
- 专科诊所
- 家庭护理
- 其他的
分销渠道
- 医院药房
- 零售药店
- 网上药店
- 其他的
中枢性性早熟 (CPP) 治疗市场区域分析/见解
对中枢性性早熟 (CPP) 治疗市场进行了分析，并按类型、月份、给药途径、性别、最终用户和分销渠道提供了市场规模洞察和趋势。
中枢性性早熟 (CPP) 治疗市场报告涵盖的主要国家 包括亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾和亚太地区 (APAC) 其他地区。
由于性早熟发生率的增加和女孩人口的增加，日本预计将在亚太市场占据主导地位。
由于生活方式的快速变化和治疗方案的广泛使用，中国是增长最快的国家之一。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析的同时，还考虑了亚太地区品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和亚太中枢性性早熟 (CPP) 治疗市场份额分析
中枢性性早熟 (CPP) 治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、亚太地区业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对中枢性性早熟 (CPP) 治疗市场的关注有关。
中枢性性早熟 (CPP) 治疗市场的主要参与者包括：
- 赛诺菲（法国）
- 辉瑞公司（美国）
- 葛兰素史克公司 (英国)
- 诺华公司（瑞士）
- AbbVie Inc.（美国）
- F. Hoffmann-La Roche Ltd.（瑞士）
- Mylan NV（美国）
- Teva Pharmaceutical Industries Ltd.（爱尔兰）
- 益普生制药（法国）
- Arbor Pharmaceuticals（美国）
- Tolmar Pharmaceuticals, Inc.（美国）
- GP Pharm（西班牙）
- Debiopharm（瑞士）
- 大雄制药有限公司（韩国）
- 太阳制药工业有限公司 (印度)
- 武田药品工业株式会社 (日本)
- Endo International plc（爱尔兰）
- 阿斯利康（英国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
